121221-07-6

Basic information

• Product Name: 2-Chloro-N-quinolin-3-yl-acetaMide, 98+%
• Synonyms: 2-Chloro-N-quinolin-3-yl-acetaMide, 98+%;2-Chloro-N-3-quinolinylacetamide;2-chloro-N-(3-quinolyl)acetamide;2-chloro-N-quinolin-3-yl-ethanamide
• CAS NO: 121221-07-6
• Molecular Formula: C₁₁H₉ClN₂O
• Molecular Weight: 220.65496
• Mol File: 121221-07-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.368
• CAS DataBase Reference: 2-Chloro-N-quinolin-3-yl-acetaMide, 98+%(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-N-quinolin-3-yl-acetaMide, 98+%(121221-07-6)
• EPA Substance Registry System: 2-Chloro-N-quinolin-3-yl-acetaMide, 98+%(121221-07-6)

Safety Data

• Hazardous Substances Data: 121221-07-6(Hazardous Substances Data)

Usage

General Description

2-Chloro-N-quinolin-3-yl-acetamide, 98+% is a chemical compound with a purity of at least 98%. It is an organic compound that contains a chlorine atom and a quinoline ring structure. This chemical may have applications in pharmaceutical research and development, organic synthesis, and as a building block for the production of other compounds. It is important to handle this compound with care as it may be hazardous if not used appropriately and in accordance with safety guidelines and regulations.

Upstream product

• 580-17-6 3-aminoquinoline 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 121221-01-0 3-<3-(triethylsilyl)propylaminoacetylamino>quinoline dihydrochloride 

Relevant articles and documents

Development of quinoline-based hybrid as inhibitor of methionine aminopeptidase 1 from Leishmania donovani

Methionine aminopeptidase 1 (MetAP1) is a target for drug discovery against many adversaries and a potential antileishmanial target for its role in N-terminal methionine processing. As an effort towards new inhibitor discovery against methionine aminopeptidase 1 from Leishmania donovani (LdMetAP1), we have synthesized a series of quinoline-based hybrids, that is (Z)-5-((Z)-benzylidine)-2-(quinolin-3-ylimino)thiazolidin-4-ones (QYT-4a-i) whose in vitro screening led to the discovery of a novel inhibitor molecule (QYT-4h) against LdMetAP1. The compound QYT-4h showed nearly 20-fold less potency for human MetAP1 and had drug-like features. Time–course kinetic assays suggested QYT-4h acting through a competitive mode by binding to the metal-activated catalytic site. Notably, QYT-4h was most potent against the physiologically relevant Mn(II) and Fe(II) supplemented forms of LdMetAP1 and less potent against Co(II) supplemented form. Surface plasmon resonance and fluorescence spectroscopy demonstrated high affinity of QYT-4h for LdMetAP1. Through molecular modelling and docking studies, we found QYT-4h binding at the LdMetAP1 catalytic pocket occupying both the catalytic and substrate binding sites mostly with hydrogen bonding and hydrophobic interactions which provide structural basis for its promising potency. These results demonstrate the feasibility of employing small-molecule inhibitors for selective targeting of LdMetAP1 which may find use to effectively eliminate leishmaniasis.

Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection

Butyrylcholinesterase (BChE) has been considered as a potential therapeutic target for Alzheimer's disease (AD) because of its compensation capacity to hydrolyze acetylcholine (ACh) and its close association with Aβ deposit. Here, we identified S06-1011 (hBChE IC50 = 16 nM) and S06-1031 (hBChE IC50 = 25 nM) as highly effective and selective BChE inhibitors, which were proved to be safe and long-acting. Candidate compounds exhibited neuroprotective effects and the ability to improve cognition in scopolamine- and Aβ1-42 peptide-induced cognitive deficit models. The best candidate S06-1011 increased the level of ghrelin, a substrate of BChE, which can function as improving the mental mood appetite. The weight gain of the S06-1011-treated group remarkably increased. Hence, BChE inhibition not only plays a protective role against dementia but also exerts a great effect on treating and nursing care.